- CureVac BV CVAC said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.
- The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV.
- “The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis,” the company said in its statement.
- The CureVac vaccine is based on mRNA technology, like the ones developed by Moderna Inc MRNA and Pfizer Inc PFE - BioNTech SE BNTX.
- In its Q1 earnings release, the company said CV2CoV data readout from the pivotal Phase 2b/3 trial is expected in June 2021.
- Price Action: CVAC shares are down 3.5% at $107.56 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
